Introduction {#Sec1}
============

In the twenty-first century, tuberculosis (TB) continues to be one of the world's major health challenges. TB is a deadly communicable disease that is primarily transmitted from human to human by droplet infection, and it is a major health burden in both developed and developing countries. Approximately 9.0 million people developed TB, and 1.5 million died from the disease in 2013 \[[@CR1]\]. Of the 9.0 million estimated cases, 56% were in Southeast Asian and Western Pacific regions \[[@CR2]\]. China accounted for 11% of the 9.0 million estimated TB cases, and 11,528 TB cases were confirmed in Taiwan \[[@CR3]\]. Male, elderly and immunocompromised patients, including those with HIV, patients with poorly controlled diabetes mellitus or chronic kidney disease or those receiving immunosuppressant treatments, are generally more susceptible to the disease \[[@CR4]\]. Healthcare workers who are exposed to TB also have higher risks of being infected \[[@CR5]\].

Due to the side effects of the drugs \[[@CR6], [@CR7]\], poor medication compliance and the problem of development of drug-resistant TB, global investment in TB research is needed \[[@CR8]\]. Among the first-line anti-TB drugs, side effects of hepatotoxicity have been reported to be associated with isoniazid, rifampin and pyrazinamide; cutaneous reactions with isoniazid, pyrazinamide and ethambutol; gastrointestinal intolerance with rifampin; retrobulbar neuritis with ethambutol; and ototoxicity with streptomycin \[[@CR9]--[@CR11]\]. Long-term respiratory symptoms and impairment of pulmonary function affect patients' quality of life after completing TB treatment. The respiratory comorbidities were identified in more than half of microbiologically cured TB patients \[[@CR12]\]. Despite successful treatment of TB, residual impairments persist, and chronic complications or sequelaes can arise from structural or vascular alterations at disease sites \[[@CR13], [@CR14]\]. Many patients with chronic illness may seek complementary therapies \[[@CR15]\], especially Chinese Medicine (CM) in Asian countries \[[@CR16], [@CR17]\]. CM, which originated in ancient China, is defined as comprehensive healthcare skills and practice for the maintenance of health and treatment of disease based on the beliefs of holism \[[@CR18]\] and experiences of pattern identification/syndrome differentiation handed down from generation to generation \[[@CR19]\]. In Taiwan, CM is important and popular among different categories of complementary therapies, and is regarded as one of the mainstream therapies with coverage of the National Health Insurance (NHI) program \[[@CR17]\]. "CM" usually refers to the overall treatment modalities, and services of CM covered by the NHI program, which includes Chinese medicines, acupuncture, moxibustion and Chinese traumatology therapy \[[@CR20]\]. "Chinese medicines" usually refers to herbs or herbal products which can be classified into single-herb products and herbal formulas (multi-herb products) \[[@CR21]\]. In Taiwan, herbal products (concentrated scientific herbal granules) covered by the NHI program are manufactured by GMP-certified pharmaceutical companies \[[@CR22]\].

The ancient CM literature did not use the word "TB", but rather considered this pulmonary condition to be related to a syndrome of lung consumption characterized by cough, hemoptysis, tidal fever, night sweats and emaciation due to consumptive or exhaustive overstrain. It was reported that Chinese medicines combined with conventional medicine has beneficial effects for inhibiting Mycobacterium, strengthening the immune system of the body, enhancing the effect of anti-TB drugs, reducing drug resistance, and being relatively safe \[[@CR23]--[@CR25]\]. While several studies have investigated the use of CM in the care of TB patients \[[@CR23]\], there is a lack of this kind of survey on the use of CM among patients with a medical history of TB and complicated with long-term respiratory discomforts.

We intended to investigate the utilization of CM among patients with a medical history of TB complicated with long-term respiratory discomforts in this study. The results of this study will be useful for future clinical trials and pharmacological investigations regarding efficacy and safety.

Materials and methods {#Sec2}
=====================

Data sources {#Sec3}
------------

The NHI program was established in Taiwan in 1995. The program was highly representative of samples of Taiwan's general population because the reimbursement policy is universal and mandatory. The coverage rate of this compulsory health insurance program reached almost 95% in 1997 \[[@CR26]\] and 99.4% at the end of 2010 in Taiwan \[[@CR27]\]. CM services that are reimbursed in the NHI program include Chinese medicines, acupuncture, moxibustion, and Chinese traumatology therapy \[[@CR28]\]. The National Health Insurance Administration provided the registration files and original claims data to the National Health Research Institutes, which established and managed the National Health Insurance Research Database (NHIRD) for research purposes. This study was based in part on data from the NHIRD. It contains data comprising demographic characteristics, medical care facilities, outpatient and inpatient visits, visit dates, diagnostic codes, management, prescriptions and medical expenditures. We acquired a randomly selected sample consisting of one million individuals (Longitudinal Health Insurance Database 2000; LHID 2000) from the NHIRD managed and released by the National Health Research Institutes, Taiwan. The diagnostic codes were from the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) formats.

Ethical consideration {#Sec4}
---------------------

This study followed the ethical standards of the responsible committee and with the Helsinki Declaration of 1964 and later versions. All the datasets were de-identified and encrypted before released by the National Health Research Institutes, Taiwan. All of the individuals or care providers could not be identified in the database. Patient consent was exempted for the total anonymity of all research data in this study. Therefore, the Research Ethics Committee of China Medical University and Hospital approved this study and waived the requirement for informed consent (CMUH104-REC2--115).

Study population {#Sec5}
----------------

Patients newly diagnosed with TB (ICD-9-CM codes 010--018 and A02) (*n* = 36,660) were selected from the database. To avoid the inclusion of patients who did not have the disease, we set the inclusion criteria to allow only patients who were newly diagnosed with TB from January 1, 1997, to December 31, 2010, with clinical records from at least 2 months and treatment with first-line TB medication prescriptions (isoniazid, rifampin, pyrazinamide & ethambutol) (*n* = 8306). Because the prevalence and etiology of TB infections in children were different, and the medical services-seeking behaviors among children or adolescents were mainly dominated by their parents, children with TB infections were not included in our objectives. Therefore, we further excluded patients who were less than 18 years of age or who had missing information related to birth and sex (*n* = 401). A total of 7905 TB patients were then included. Therefore the sample inclusion criteria is as following: (1) TB diagnosed between January 1, 1997 and December 31, 2010. (2) 18 years old or over. (3) Clinical records for at least 2 months with complete demographic information (4) Record of treatment with first-line TB medication prescriptions. CM users were defined as those who had visited CM clinics and had CM outpatient clinical records of TB or respiratory diseases (ICD-9-CM codes 786.x or 460--519). Non-CM users were defined as those who never visited CM clinics after the initial diagnosis of TB. To investigate TB patients complicated with long- term respiratory discomforts, we further excluded those clinical visits with a non-TB or respiratory diagnosis (*n* = 3980). Finally, a total of 3925 TB patients were then categorized into CM users (*n* = 2051) and non-CM users (*n* = 1874) (Fig. [1](#Fig1){ref-type="fig"}). Taiwan is a country with a population of 23 million. Taiwan has a geographical area of 36,000 km^2^. There were 23 cities and 359 townships in Taiwan and many of its residents live within urban cities. The residential areas of 23 cities in Taiwan were classified into 4 levels of urbanization based on the population density (people/km^2^), the ratio of the population with varying educational levels, and the number of physicians per 100,000 people. Level 1 represents the highest urbanized level, while 4 represents the lowest level. Levels 1 and 2 of this urbanization were defined as urban areas, while levels 3 and 4 were classified as rural areas \[[@CR29]\].Fig. 1Recruitment flow chart of subjects with tuberculosis (TB) from one million randomly selected samples in the National Health Insurance Research Database (NHIRD) from 1997 to 2000 in Taiwan. The inclusion criteria of patients (*n* = 7905) with history of TB (ICD-9-CM codes 010--018 and A02) were: (1) TB diagnosed between January 1, 1997 and December 31, 2010 (2) 18 years old or over (3) Clinical records for at least 2 months with complete demographic information (4) Record of treatment with first-line TB medication prescriptions. CM users for conditions other than respiratory discomforts (*n* = 3980) were excluded. Finally, a total of 3925 TB patients were categorized as: CM users for respiratory discomforts (*n* = 2051) and non-CM users (*n* = 1874)

Prescription of Chinese medicines {#Sec6}
---------------------------------

We listed the herbal formulas by their phonetic pin-yin name and single herbs by their phonetic pin-yin name, Chinese material medica name and plant name. Indications for the herbal formulas and single herbs were based on CM theory \[[@CR30], [@CR31]\]. Full botanical names were in accordance with the International Plant Names List (IPNI; <http://www.ipni.org>) and The Plant List (<http://www.theplantlist.org>/) \[[@CR32]\]. An open-sourced freeware Node XL (<http://nodexl.codeplex.com>/) was utilized to identify the core patterns of prescriptions for TB patients, and the most common co-prescribed Chinese medicines were demonstrated in this network analysis. As previously described \[[@CR33]\], the larger of the spots with thicker-line widths indicated significant prescription patterns and counts of close connections between formulas and herbs in the network figure.

Statistical analysis {#Sec7}
--------------------

All statistical analyses were performed using SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA). Univariate analysis was utilized to compare the CM users with the non-CM users. Data analysis comprised descriptive statistics, including the frequency of herbal prescriptions, patient demographic characteristics, indications for the TCM prescription, and the most frequently prescribed herbal formulas and herbs for treating TB. The chi-square test was used to examine the relationships between the categorical variables and to examine the differences between CM users and non-CM users. A *P*-value of \< 0.05 was considered statistically significant.

Results {#Sec8}
=======

In this study, we identified 52.25% (*n* = 2051) patients with a medical history of TB who had visited CM clinics and had CM outpatient clinical records of TB or respiratory diseases (Fig. [1](#Fig1){ref-type="fig"}). Those who were female, younger (18--39 y/o), and lived in higher urbanized areas (levels 1 and 2) were relatively more likely to use CM. The median duration between newly diagnosed TB and the first CM consultation was 1068 days (Table [1](#Tab1){ref-type="table"}).Table 1Demographic characteristics of the patients with tuberculosis in TaiwanVariableNon-CM usersCM users^†^*P*-valuen = 1874 (44.753%)n = 2051 (52.25%)n%n%Sex\<.0001\* Female35418.8986141.98 Male152081.11119058.02Age at baseline (year)\<.0001\* 18--291005.3429314.29 30--391276.7824211.8  ≥ 40164787.89151673.92 Mean (SD)64.06 (17.68)53.25 (18.03)\<.0001‡Urbanization\<.0001\* 1 (highest)40821.7752925.8 24312360729.61 332717.4534516.83 435418.8930614.93 5+ (lowest)35418.8926312.83Drug used rifampin181997.07200597.760.1714\* ethambutol179695.84198596.780.116\* isoniazid180296.16197296.150.9874\* pyrazinamide158184.36179887.660.0028\* levofloxacin45624.3353626.130.1948\* streptomycin1316.991135.510.055\* kanamycin733.9813.950.9308\* prothionamide180.96241.170.5237\* cyclosporine20.1150.240.456\$ moxifloxacin0010.05--Interval between the onset oftuberculosis and the first CM consultation, days(median)1395 (1068)--‡ t-test; \* chi-square; \$ Fisher's exact testAbbreviation: *SD* standard deviation, *CM* Chinese Medicine† CM users referred to patients with history of TB who had visited CM clinics and had CM outpatient clinical records of tuberculosis or respiratory diseases

Regarding the treatment modes employed among the CM users, approximately 95% of CM users (*n* = 1944) received only Chinese medicines, 5.2% of patients received combined treatment with both Chinese medicines and acupuncture, and the remaining 0.2% of patients received only acupuncture treatments. Among all CM users (patients with a medical history of TB who had visited CM clinics and had CM outpatient clinical records of TB or respiratory diseases; *n* = 2051), 90.15% visited CM clinics 1--3 times annually, while 4.58% patients consulted CM doctors more than 6 times/year (Table [2](#Tab2){ref-type="table"}).Table 2Distribution of CMs according to type of CM treatment received in patients with tuberculosis, stratified by the number of outpatient visitsNumber of CM visits (times/per year)Only Chinese medicinesOnly acupunctureCombination of both treatmentsTotal *n* = 2051 (100%)*n* = 1944 (94.78%)*n* = 4 (0.20%)*n* = 103 (5.02%)n (%)n (%)n (%)n (%)1--31763 (90.69)4 (100)82 (76.61)1849 (90.15)4--696 (4.94)012 (11.65)108 (5.27)\> 685 (4.37)09 (8.74)94 (4.58)Abbreviation: *CM* Chinese Medicine

The frequency distribution of disease categories related to respiratory discomforts and comorbidities that patients who had been diagnosed TB was analyzed (Table [3](#Tab3){ref-type="table"}). Compared to the non-CM users, the frequencies of outpatient visits among TB patients who used CM were statistically higher across almost all discomforts and comorbidities, except swelling, mass, and lump in chest (Table [3](#Tab3){ref-type="table"}). More than 70% of TB patients used CM because of acute respiratory infections, cough, chronic obstructive pulmonary disease and allied conditions, and other diseases of upper respiratory tract. These results could indicate the comorbidities and complications of TB and may serve as an explanation for why TB patients complicated with long-term respiratory discomforts turn to CM doctors for help (Table [3](#Tab3){ref-type="table"}). We further investigated the prescription pattern of Chinese medicines and identified the ten most commonly prescribed formulas and single herbs. The ten most commonly prescribed single herbs and herbal formulas were analyzed and are listed in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}, respectively. The most commonly prescribed herbal formulas and single herb were Xiao-Qing-Long-Tang, and Radix Platycodonis (Jie-Geng), respectively.Table 3Frequency of different diseases related to symptoms of respiratory discomforts or complications in tuberculosis patientsDisease (ICD-9-CM)Non-CM usersCM users^†^*P* value\*n%n%Acute respiratory infections (460--466)140574.97202298.59\<.0001Other diseases of upper respiratory tract (470--478)56430.1154475.28\<.0001Pneumonia and influenza (480--488)115661.69139367.92\<.0001Chronic obstructive pulmonary disease and allied conditions (490--496)130769.74166381.08\<.0001Pneumoconioses and other lung diseases due to external agents (500--508)1839.771467.120.0028Other diseases of respiratory system (510--519)95250.885341.59\<.0001Dyspnea and respiratory abnormalities (786.0)31316.748823.79\<.0001Stridor (786.1)251.331246.05\<.0001Cough (786.2)47525.35151974.06\<.0001Hemoptysis (786.3)21111.2637518.28\<.0001Abnormal sputum (786.4)160.85492.390.0002Chest pain (786.5)37520.0193045.34\<.0001Swelling, mass, or lump in chest (786.6)321.71502.440.1101Hiccough (786.8)90.48401.95\<.0001Other symptoms involving respiratory system and chest (786.9)231.23522.540.0028\* chi-square testAbbreviation: SD standard deviation, *CM*, Chinese Medicine†CM users referred to patients with history of TB who had visited CM clinics and had CM outpatient clinical records of tuberculosis or respiratory diseasesTable 4Ten most commonly prescribed herbs for patients with tuberculosisPin-yin nameChinese Materia Medica nameBotanical nameIndicationNumber of person-daysJie-GengRadix Platycodonis*Platycodon grandiflorus* (Jacq.) A.DCCough, large amount of sputum, sore throat18,779Bei-MuBulbus Fritillariae Thunbergii*Fritillaria thunbergii* Miq.Lung heat with thick phlegm, cough due to yin deficiency18,460Xing-RenSemen Armeniacae*Prunus armeniaca* L.var. *ansu* MaxCough with phlegm, cough in older people or weaker bodies14,610Yu-Xing- CaoHerba Houttuyniae*Houttuynia cordata* Thunb.Fever, Inflammation of the respiratory tract8978Gua-Lou- RenSemen Trichosanthis*Trichosanthes kirilowii* MaximHot cough with sticky phlegm8905Gan-CaoRadix Glycyrrhizae*Glycyrrhiza uralensis* FischLung TB, cough with abundance of phlegm, tired and lack of strength, palpitation and short of breath8054Huang-QinRadix Scutellariae*Scutellaria baicalensis* GeorgiCough due to heat syndromes, infection, and hemoptysis7991Mai-Men-DongRadix Ophiopogonis*Ophiopogon japonicus* (Thunb.) Ker Gawl.Cough, weakness, consumption, short of breath, heat from yin deficiency6934Dan-ShenRadix Salviae Miltiorrhizae*Salvia miltiorrhiza* Bge.Restlessness, insomnia, irritability, blood deficiency and blood stasis6508Wu-Wei- ZiFructus Schisandrae*Schisandra chinensis* (Turcz.) Baill.Wheezy cough, palpitations, and thirst due to yin deficiency6154Table 5Ten most commonly prescribed formulas for patients with tuberculosisPin-yin nameConstitutionsIndications in TCMNumber of person- daysPin-yin nameChinese Materia Medica nameBotanical nameXiao-Qing-Long-TangMa-HuangHerba Ephedrae*Ephedra sinica* Stapf.Coughing and wheezing with copious, white, stringy sputum that is difficult to expectorate, stifling sensation in the chest, chronic water metabolism problems and thin mucus associated with weakness of lung16,050Gui-ZhiRamulus Cinnamomi*Cinnamomum cassia* BlumeGan-JiangRhizoma Zingiberis*Zingiber officinale* RoscXi-XinHerba Asari*Asarum heterotropoides* F. SchmidtWu-Wei-ZiFructus Schisandrae*Schisandra chinensis* (Turcz.) Baill.Bai-ShaoRadix Paeoniae Alba*Paeonia lactiflora* Pall.Ban-XiaRhizoma Pinelliae*Pinellia ternate* (Thunb.) MakinoGan-CaoRadix Glycyrrhizae*Glycyrrhiza uralensis* FischXin-Yi-Qing-Fei-TangXin-YiMagnoliae Flos*Magnolia biondii* Pamp.Lung-heat cough with yellow phlegm, and accumulation of lung heat with nasal congestion15,035Huang-QinRadix Scutellariae*Scutellaria baicalensis* GeorgiMai-Men-DongRadix Ophiopogonis*Ophiopogon japonicus* (Thunb.) Ker Gawl.Zhi-ZiFructus Gardeniae*Gardenia jasminoides* J.EllisShi- GaoGypsum fibrosum*Hydrous Calcium* SulfateZhi-MuRhizoma Anemarrhenae*Anemarrhena asphodeloides* BungeSheng-MaRadix Cimicifugae*Cimicifuga foetida* L. var., intermedia, RegelBai-HeBulbus Lilii*Lilium brownii* F. E. Br.ex MeillezPi-Pa-YeFolium Eriobotryae*Eriobotrya japonica* (Thunb) LindlGan-CaoRadix Glycyrrhizae*Glycyrrhiza uralensis* FischMa-Xing-Gan-Shi-TangMa-HuangHerba Ephedrae*Ephedra sinica* Stapf.Fever with thirst, wheezing, coughing, labored breathing caused by heat lodged in the lungs where it obstructs the flow of qi14,185Xing-RenSemen Armeniacae*Prunus armeniaca* L.var. *ansu* MaximShi- GaoGypsum fibrosum*Hydrous Calcium* SulfateGan-CaoRadix Glycyrrhizae*Glycyrrhiza uralensis* FischDing-Chuan-TangMa-HuangHerba Ephedrae*Ephedra sinica* Stapf.Coughing and wheezing with thick, yellow sputum that is difficult to expectorate. Fever and labored breathing caused by the disrupted flow of lung qi that transforms into heat10,664Xing-RenSemen Armeniacae*Prunus armeniaca* L.var. *ansu* MaximBan-XiaRhizoma Pinelliae*Pinellia ternate* (Thunb.) MakinoHuang-QinRadix Scutellariae*Scutellaria baicalensis* GeorgiSang-Bai-PiCortex Mori*Morus alba* L.Bai-GuoSemen Ginkgo*Ginkgo biloba* L.Su-ZiFructus Perillae*Perilla frutescens* (L.) Britton.Kuan-Dong-HuaFlos Farfarae*Tussilago farfara* L.Gan-CaoRadix Glycyrrhizae*Glycyrrhiza uralensis* FischYin-Qiao-SanJin-Yin-HuaFlos Lonicerae*Lonicera japonica* Thunb.Fever, headache, thirst, cough with chills caused by warm pathogens or wind-heat entering the body and attacking the lungs10,106Lian-QiaoFructus Forsythiae*Forsythia suspensa* (Thunb.) VahlJie-GengRadix Platycodonis*Platycodon grandiflorus* (Jacq.) A.DC.Niu-Bang ZiFructus Arctii*Arctium lappa* LBo-HeHerba Menthae haplocalycis*Mentha haplocalyx* BriqDan-Dou- ChiSemen Sojae preparatum*Glycine max* (L.) Merr.Jing-JieHerba Schizonepetae*Schizonepeta tenuifolia* (Benth.)Dan-Zhu-YeHerba Lophatheri*Lophatherum gracile* BrongnLu-GenRhizoma Phragmitis recens*Phragmites communis* TrinGan-CaoRadix Glycyrrhizae*Glycyrrhiza uralensis* FischBai-He-Gu Jin-TangShu-Di-HuangRadix Rehmanniae*Rehmannia glutinosa* LiboschCoughing with blood-streaked sputum, wheezing, dry and sore throat, hot palms and soles, night sweats due to yin deficiency of lung and kidney with heat from yin deficiency9735Sheng-Di-HuangRadix Rehmanniae*Rehmannia glutinosa* LiboschMai-Men-DongRadix Ophiopogonis*Ophiopogon japonicus* (Thunb.) Ker Gawl.Bai-HeBulbus Lilii*Lilium brownii* F. E. Br.ex MeillezBai-ShaoRadix Paeoniae Alba*Paeonia lactiflora* PallDang-GuiRadix Angelicae Sinensis*Angelica sinensis* (Oliv.) DielsBei-MuBulbus Fritillariae Thunbergii*Fritillaria thunbergii* Miq.Jie-GengRadix Platycodonis*Platycodon grandiflorus* (Jacq.) A.DC.Xuan-ShenRadix Scrophulariae*Scrophularia ningpoensis* Hemsl.Gan-CaoRadix Glycyrrhizae*Glycyrrhiza uralensis* FischXing-Su-YinZi-SuFolium Perillae*Perilla frutescens* (L.) Britton.Wheezy cough, nasal congestion, low fever, headache due to a wind-cold pathogen attacking the lung9343Xing-RenSemen Armeniacae*Prunus armeniaca* L.var. *ansu* MaximJie-GengRadix PlatycodonisP*latycodon grandiflorus* (Jacq.) A.DC.Sang-Bai-PiCortex Mori*Morus alba* L.Huang-QinRadix Scutellariae*Scutellaria baicalensis* GeorgiMai-Men-DongRadix Ophiopogonis*Ophiopogon japonicus* (Thunb.) Ker Gawl.Bei-MuBulbus Fritillariae Thunbergii*Fritillaria thunbergii* Miq.Qian-HuRadix Peucedani*Peucedanum decursivum* MaximSheng-JiangRhizoma Zingiberis*Zingiber officinale* RoscJu-HongCitri Reticulatae Pericarpium Rubrum*Citrus maxima* (Burm.) Merr.Zhi-KeFructus Citri Aurantii*Citrus aurantium* L.Gan-CaoRadix Glycyrrhizae*Glycyrrhiza uralensis* FischZhi-Sou-SanJie-GengRadix Platycodonis*Platycodon grandiflorus* (Jacq.) A.DC.Coughing with slight chills and fever, an itchy throat, phlegm that is difficult to expectorate that occurs in externally contracted wind cold9275Jing-JieHerba Schizonepetae*Schizonepeta tenuifolia* (Benth.)Zi-WanAsteris Radix*Aster tataricus* L. f.Bai-BuRadix stemonae*Stemona sessilifolia* (Miq.) Miq.Bai-QianRhizoma Cynanchi Stauntonii*Cynanchum stauntonii* (Decne.) Schltr.ex H.Lev.Chen-PiPericarpium Citri Reticulatae*Citrus reticulate* BlancoGan-CaoRadix Glycyrrhizae*Glycyrrhiza uralensis* FischCang-Er-SanCang-Er-ZiXanthii Fructus*Xanthium Sibiricum* Patr. ex Widder.Nasal obstruction with purulent nasal discharge caused by an external wind pathogen obstructing the protective qi, which is governed by lung, dizziness, frontal headache9248Xin-YiMagnoliae Flos*Magnolia biondii* Pamp.Bo-HeHerba Menthae haplocalycis*Mentha haplocalyx* BriqBai-ZhiRadix Angelicae Dahuricae;*Angelica dahurica* (Hoffm.) Benth. & Hook.f. ex Franch. & Sav.Qing-Zao-Jiu-Fei-TangSang-YeFolium Mori*Morus alba* L.Wheezing, cough, dry, parched throat, dry nasal passages, headache, fever, irritability, thirst due to invasion of external warm-dryness attacking the lungs and causing damage to the lung qi and yin8795Shi-GaoGypsum fibrosum*Hydrous Calcium* SulfateGan-CaoRadix Glycyrrhizae*Glycyrrhiza uralensis* FischXing-RenSemen Armeniacae*Prunus armeniaca* L.var. *ansu* MaximMai-Men-DongRadix Ophiopogonis*Ophiopogon japonicus* (Thunb.) Ker Gawl.Pi-Pa-YeFolium Eriobotryae*Eriobotrya japonica* (Thunb) LindlE-JiaoColla Corii Asini*Equus asinus* L.Ren-ShenRadix Ginseng*Panax ginseng* C. A. MeyHu-Ma-RenSemen Sesami Nigrum*Sesamum indicum* L.

We further conducted a network analysis and found that the core patterns of herbal formulas and herbs prescribed for TB patients consisted of Ma-Xing-Gan-Shi-Tang, Bulbus Fritillariae Thunbergii (Bei-Mu), Radix Platycodonis (Jie-Geng), and Semen Armeniacae (Xing-Ren) (Fig. [2](#Fig2){ref-type="fig"}). We further summarized these findings in Fig. [3](#Fig3){ref-type="fig"}.Fig. 2The 100 most commonly prescribed herbal formulas and single herbs for patients with tuberculosis were assessed, and the core pattern of the prescriptions shows that Ma-Xing-Gan-Shi-Tang, Bei-Mu, Jie-Geng, and Xing-Ren were among the most frequently prescribed combinationsFig. 3Summarized illustration of the core prescription pattern for patients with tuberculosis in Taiwan

Discussion {#Sec9}
==========

In this study, we first observed that the median duration between newly diagnosed TB and the first CM consultation was 1068 days. Many TB patients complicated with long-term respiratory discomforts sought CM services. We then determined that Ma-Xing-Gan-Shi-Tang, Bulbus Fritillariae Thunbergii (Bei-Mu), Radix Platycodonis (Jie-Geng), and Semen Armeniacae (Xing-Ren) were the core prescriptions for patients with TB in Taiwan. To the best of our knowledge, this report describes the first nationwide population-based cohort study investigating CM utilization patterns among TB patients complicated with long-term respiratory discomforts. However, whether CM combined with modern conventional medicine has beneficial effects or risks requires further investigation.

The phenomenon that female patients with TB were relatively more likely to seek CM services is comparable to a previous Taiwanese survey demonstrating that women had a greater tendency to seek CM consultations \[[@CR34]\]. It has been reported that women are more susceptible to side effects from anti-TB drugs due to higher CYP3A activity \[[@CR11], [@CR35]\], although men are more susceptible to TB than women \[[@CR36]\]. Women may exhibit more help-seeking behaviors than men and are more likely to seek complementary therapies when they suffer from chronic or catastrophic illness \[[@CR37], [@CR38]\].

We also observed that younger patients (18--39 y/o) and those who lived in more urbanized areas were relatively more likely to choose CM, in accordance with previous studies \[[@CR38], [@CR39]\]. Patients younger than 40 years old are likely to be more aware of alternative therapeutic choices. A previous report had shown that women, people with high socioeconomic status, higher education levels, self-perceived poor health status, and people who exercise regularly tend to visit CM services more often in Taiwan \[[@CR40]\]. Patients who reside in more urbanized areas usually have a higher socioeconomic status and fewer barriers to accessing medical services \[[@CR41], [@CR42]\]. The time and money spent on transportation may also lead to a significant inequality in contact with the health system \[[@CR43]--[@CR45]\]. Therefore, people who live in urbanized areas have a greater tendency to use CM services.

In Taiwan, patients with a diagnosis of TB are required to receive pharmacological therapy to control TB infection with monitoring by local health officers based on the government's health policy \[[@CR46]\]. The included patients who had been diagnosed with TB should have received standard anti-TB treatment. In Taiwan, recommended standard treatment for adult respiratory TB consists of a regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, followed by isoniazid, rifampicin, and ethambutol for 4 months with monitoring by local health officers according to governmental policy \[[@CR46]\]. The total treatment course takes approximately 6 months in newly diagnosed patients \[[@CR46]\]. The median duration between newly diagnosed TB and the first CM consultation was 1068 days. During the follow-up period, patients might seek CM consultation due to symptoms of respiratory discomfort or complications. In addition to respiratory illness, they may also experience other symptoms related to the anti-TB treatment, such as skin rash or drug fever, GI intolerance, nausea, vomiting, visual toxicity, hearing disturbances and arthralgia \[[@CR9], [@CR47]--[@CR49]\]. The NHI insurance coverage for CM treatments may play a considerable role in patients' tendency to seek CM consultations. Medical services in both Western medicine and CM have been promoted due to the high coverage of the NHI program. Furthermore, the cost of co-payment for concentrated scientific herbal granules is approximately \$15 U.S. dollars per month under the NHI Program in Taiwan. The tendency of patients to seek CM may continue to increase since the co-payment for Chinese medicines is relatively low \[[@CR50]--[@CR53]\].

Among patients with TB, most CM users (94.78%) received only Chinese medicines, which is consistent with previous studies investigating other respiratory diseases for which herbal products are frequently used as treatment in CM visits in Taiwan \[[@CR52], [@CR54]\]. In patients with adult-onset asthma, 76.7% patients who visited CM physicians received Chinese medicines \[[@CR54]\], and 97.1% of the CM-treated rhinosinusitis subjects were prescribed Chinese medicines \[[@CR52]\].

Regarding the disease categories of the CM users identified in Table [3](#Tab3){ref-type="table"}, most of TB patients used CM because of acute respiratory infections, cough, chronic obstructive pulmonary disease and allied conditions, and other diseases of upper respiratory tract. It was reported that complications of TB include bacterial pneumonia, cor pulmonale, pneumothorax, and acute respiratory failure. Complications of TB could result in progression of functional pulmonary impairment and structural lung destructions \[[@CR14], [@CR55]\]. Patients with a prior TB diagnosis were more than twice as likely to have lung airflow obstruction \[[@CR56]\]. Furthermore, the complications of respiratory diseases can be independent predictor of shorter survival among patients with TB \[[@CR57]\]. TB patients might also turn to CM doctors in the hopes of relieving their symptoms and improving their health \[[@CR58]\].

It must be noted that TB did not appear as a disease name in the records of the Chines medical literature. However, ancient people had observed the disease, and the symptoms and signs of TB and its related illness had been recorded and discussed in the Chinese medical literature. The prescriptions of CM were in accordance with the concepts of TB in CM, which were related to chronic cough with symptoms and signs of consumption or exhaustion. The prescriptions were prescribed after pattern identification and syndrome differentiation based on the theory of CM. Most of the prescriptions listed in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} are helpful for relieving symptoms caused by yin and qi deficiency of the lung with wind contraction, which corresponds to the respiratory symptoms related to long-term respiratory discomforts \[[@CR19]\].

Among the single herbs identified in the core prescriptions, the herb Bulbus Fritillariae Thunbergii has been commonly used as an antitussive agent \[[@CR59]\]. Its isosteroidal alkaloids have been reported to have tracheobronchial relaxant activity \[[@CR60]\]. Radix Platycodonis has been used for bronchitis, tonsillitis, and laryngitis in ancient times. The pharmacological constituent Platycodin D in Radix Platycodonis has demonstrated anti-inflammatory, antitumor \[[@CR61]\], antinociceptive and immunomodulatory activities. Immunostimulatory effects have been revealed via the suppression of IL-6 and TNF-α contents \[[@CR62]\] and enhancement of the killing activities of natural killer cells \[[@CR61]\]. Radix Platycodonis also inhibits OVA-induced airway inflammation and regulates the production and secretion of airway mucin \[[@CR63]\]. Furthermore, Radix Platycodonis has often served as an expectorant in diverse inflammatory pulmonary diseases \[[@CR64]\]. The other herb of the core prescriptions, Semen Armeniacae, has anti-inflammatory and analgesic effects by suppressing PGE2 and NO production \[[@CR65]\]. The amygdalin found in it has been used as an antitussive, anti-asthmatic, anticancer agent \[[@CR66], [@CR67]\].

In addition to the above three herbs, other herbs have been reported to relieve respiratory symptoms or reduce inflammation. Herba Houttuyniae (Yu-Xing- Cao) has been reported to relieve fever, cough and asthma with anti-inflammatory \[[@CR68]\] and antiviral activities \[[@CR69]\]. This herb inhibits the production of pro-inflammatory cytokines via inhibition of the NF-κB signaling pathway in HMC-1 human mast cells \[[@CR70]\]. Semen Trichosanthis (Gua-Lou- Ren) has anti-inflammatory, and antibacterial activities \[[@CR71]\] and immunomodulatory effects \[[@CR72]\]. Ophiopogonin-D in Radix Ophiopogonis (Mai-Men-Dong) may be beneficial for reducing the excitability of parasympathetic ganglionic neurons in the airways and cholinergic control of airway function, and its antitussive effects might be due to the activation of K+ channels and hyperpolarization of paratracheal neurons \[[@CR73]\]. Radix Salviae Miltiorrhizae (Dan-Shen) could be helpful for reducing lung fibrosis \[[@CR74]\]. This species has been reported to exhibit anti-inflammatory and antioxidative effects \[[@CR75]\]. Radix Scutellariae (Huang-Qin) has shown pharmacological effects that are anti-inflammatory, antitumor and hepato-protective. Additionally, these extracts have antioxidant, antibacterial and antiviral effects \[[@CR76]\]. Research has indicated that a decoction containing Fructus Schisandrae (Wu-Wei-Zi) helps to prevent alveolitis and the development of pulmonary fibrosis \[[@CR77]\]. Liver-protective effects of Fructus Schisandrae via the inhibitory effect of CYP-3A4 activity have been reported \[[@CR78]\] and may also ameliorate the side effects of hepatitis resulting from the use of anti-TB medication.

Among the herbal formulas identified in this research, Ma-Xing-Gan-Shi-Tang is one of the core prescriptions. It has been used to treat asthma \[[@CR79]\] and fever associated with pneumonia. It possesses anti-asthmatic, anti-pyretic, anti-inflammatory, and antitussive effects \[[@CR80], [@CR81]\]. Xiao-Qing-Long-Tang has anti-inflammatory, antiviral, and anti-allergy activities \[[@CR82]\], and it can reduce inflammation in lung tissue via an anti-apoptotic effect and inhibition of cytokine release, as well as prevent pulmonary fibrosis \[[@CR83]--[@CR86]\]. Ding-Chuan-Tang has shown anti-asthmatic effects in clinical studies \[[@CR87]\]. Its protective effects against lung injury in asthma occurs by suppressing the production of pro-inflammatory cytokines with significantly reduced inflammatory cell infiltration, goblet cell proliferation, collagen deposition, and damage in the bronchi and alveoli \[[@CR88]\]. Xin-Yi-Qing-Fei-Tang has been commonly used for rhinitis \[[@CR51], [@CR52]\] and has been shown to reduce eosinophil, serum IgE and IL-4 levels \[[@CR89]\]. Clinical studies have reported that Yi-Qiao-San may be helpful for patients with H1N1 influenza to reduce the duration of fever \[[@CR90]\]. Lung cancer patients displayed better physical function, role function and cumulative survival after receiving combination treatments of a formula containing Bai-He-Gu Jin-Tang with Western medicine \[[@CR91]\].

There are some limitations to our study. First, the herbal products purchased at the patients' own expense in addition to the NHI program products were not included in this study. However, because the co-payment of herbal products through the NHI program was much less than the market cost, the possibility of purchasing herbs outside the NHI program was relatively low. In addition, compliance to prescription regimens was difficult to measure. Finally, this study focuses on the utilization of CM in patients with TB. In the future, a high-quality randomized controlled clinical trial with imaging data and species cultures to determine the efficacy of Chinese medicines for TB is expected.

Conclusions {#Sec10}
===========

Our study found that many TB patients complicated with long-term respiratory discomforts sought CM services in Taiwan. Those who were 18--39 y/o, female, and who lived in urbanized areas tended to use CM. The prescription patterns identified in this study could be useful for future clinical studies or pharmacological investigations.
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